Careers

Join Factor Bioscience and become part of a team working to invent new technologies to treat disease and improve health.

Our research lab and ISO Class 7 cleanroom facility are both located at our headquarters in Cambridge, Massachusetts.

Join Us

Associate Scientist

Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist. In this position, you will create advanced mRNA and cell-engineering technologies for the development of new medicines for patients with devastating diseases including Parkinson's disease, Crohn's disease, dystrophic epidermolysis bullosa, and cancer.

Associate Scientist (Chemistry)

Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist. In this position, you will create advanced mRNA and cell-engineering technologies for the development of new medicines for patients with devastating diseases including Parkinson's disease, Crohn's disease, dystrophic epidermolysis bullosa, and cancer.

Factor News

January 9, 2024

Factor Bioscience Announces U.S. Department of Defense Grant to Develop Gene-Edited Cell Therapies

-Leverages Factor’s extensively patented mRNA, cell-reprogramming, and gene-editing technologies -Cell therapy candidates will initially be developed for the treatment of Duchenne muscular dystrophy (“DMD”) -Other planned applications include infectious, inflammatory, and autoimmune indications CAMBRIDGE, Mass., January 9, 2024 /PRNewswire/ — Factor Bioscience Inc. (“Factor”), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, announced […]

February 28, 2023

Factor Bioscience Announces Publication of Preclinical Results of Aerosolized mRNA For the Treatment of Pneumonia

-mRNA encoding immunomodulatory proteins IκBα-SR and SOD3 ameliorated symptoms in bacterial pneumonia model -Factor is investigating nebulized mRNA formulations for other therapeutic indications and next-generation vaccine applications CAMBRIDGE, Mass., February 28, 2023 /PRNewswire/ — Factor Bioscience Inc. (“Factor”), a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced the results of preclinical testing of […]

February 22, 2023

Eterna Therapeutics Enters Into Option and License Agreement With Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

CAMBRIDGE, MASS. – February 22, 2023 – Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a preclinical-stage biotechnology company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced that it has entered into an exclusive option and license agreement (the “Agreement”) with Lineage Cell Therapeutics, Inc.  (“Lineage”) for the development of novel induced hypoimmune […]